Novocure Ltd is an innovative oncology company headquartered in Saint Helier, Jersey, specializing in the development and commercialization of its proprietary tumor-treating fields (TTFields) therapy, primarily delivered via its flagship product, Optune. This unique approach aims to disrupt cancer cell division and is currently approved for the treatment of certain solid tumors, including glioblastoma multiforme and mesothelioma. As Novocure expands its clinical trials and research initiatives, it continues to strengthen its position in the oncology landscape, focusing on advancing novel therapies that address unmet medical needs in cancer care.